OncoMatch/Clinical Trials/NCT05276726

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

Is NCT05276726 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies JAB 21822 for non-small cell lung cancer.

Phase 1/2RecruitingAllist Pharmaceuticals, Inc.NCT05276726Data as of May 2026

Treatment: JAB 21822 — Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Required: KEAP1 wild-type

Required: KRAS p.g12c

Required: STK11 mutation

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 0 prior lines

Cannot have received: radiation therapy

Exception: within 3 weeks of study day 1

Therapeutic radiation therapy within 3 weeks of study day 1

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify